文献速递前列腺癌

立体定向体部放疗治疗放射性复发前列腺癌的安全性与疗效评估:系统综述与荟萃分析

Evaluation of the safety and efficacy of stereotactic body radiotherapy for radio-recurrent prostate cancer: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-12-20

该系统综述与荟萃分析纳入36项研究,评估挽救性立体定向体部放疗(SBRT)治疗放射性复发前列腺癌的疗效与严重毒性。中位无复发生存期(RFS)为36.2个月,2年、3年、5年RFS率分别为64.8%、50.7%、40.6%。全腺照射和较高生物有效剂量(BED)与改善RFS相关,严重泌尿生殖(GU)和胃肠道(GI)毒性发生率较低;但因证据水平低和研究异质性,需随机对照试验确认。

要点

  • 挽救性SBRT治疗放射性复发前列腺癌的中位RFS为36.2个月,5年RFS率为40.6%。
  • 全腺照射与局灶照射相比RFS更优,HR 1.83(95%CI 1.16-2.87),p=0.008。
  • BED 144-167.7 Gy与120-138.1 Gy相比RFS更优,HR 1.40(95%CI 1.07-1.83),p=0.015。

核心结论

  • 本研究全面评估了挽救性SBRT治疗放射性复发前列腺癌的毒性,并对RFS进行了汇总分析。
  • 全腺照射和较高BED等 factors 有望作为RFS的预后指标。
  • 由于证据水平低和研究异质性,需通过随机对照试验确认。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和EMBASE数据库至2024年7月。
  • 共分析36项研究,其中15篇论文(682例患者)用于生存曲线重建。

主要发现

  • 中位RFS为36.2个月,2年、3年、5年RFS率分别为64.8%、50.7%、40.6%。
  • 全腺照射与局灶照射相比,RFS的HR为1.83(95%CI 1.16-2.87),p=0.008,全腺照射与改善RFS相关。
  • BED 144-167.7 Gy与120-138.1 Gy相比,RFS的HR为1.40(95%CI 1.07-1.83),p=0.015,较高BED与改善RFS相关。
  • 严重(≥3级)急性GU毒性发生率为1.4%(95%CI 0.8-2.3),晚期GU毒性为3.7%(95%CI 2.6-4.9)。
  • 严重急性GI毒性发生率为0.5%(95%CI 0.2-1.1),晚期GI毒性为0.4%(95%CI 0.1-1.0);合并严重GU和GI毒性分别观察到5.8%(95%CI 4.5-7.4)和1.3%(95%CI 0.7-2.2)。

关键数值与推荐

  • 全腺照射 vs 局灶照射:HR 1.83(95%CI 1.16-2.87),p=0.008,全腺照射与改善RFS相关。
  • BED 144-167.7 Gy vs 120-138.1 Gy:HR 1.40(95%CI 1.07-1.83),p=0.015,较高BED与改善RFS相关。
  • 严重急性GU毒性:1.4%(95%CI 0.8-2.3);严重晚期GU毒性:3.7%(95%CI 2.6-4.9)。
  • 严重急性GI毒性:0.5%(95%CI 0.2-1.1);严重晚期GI毒性:0.4%(95%CI 0.1-1.0)。
  • 合并严重GU和GI毒性:5.8%(95%CI 4.5-7.4)和1.3%(95%CI 0.7-2.2)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据水平低。
  • 研究异质性。
  • 需随机对照试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic body radiotherapy (SBRT) is pivotal in managing radio-recurrent prostate cancer (PCa). This study aims to comprehensively review its efficacy and associated severe toxicities. METHODS: A thorough review of PubMed and EMBASE databases up to July 2024 was conducted to assess recurrence-free survival (RFS) with salvage SBRT across various subgroups. Survival curves were reconstructed using WebPlotDigitizer and a newly developed shiny application. RESULTS: Thirty-six studies were analyzed, with 15 papers (682 patients) contributing to survival curve reconstruction. Median RFS was 36.2 months, with 2-, 3-, and 5-year rates of 64.8%, 50.7%, and 40.6%, respectively. Factors associated with improved RFS included whole-gland irradiation [focal vs. whole, hazard ratio (HR) 1.83 (95% CI: 1.16-2.87), p = 0.008], and higher biologically effective dose (BED) [120-138.1 Gy vs. 144-167.7 Gy, HR 1.40 (95% CI: 1.07-1.83), p = 0.015]. Severe (grade ≥ 3) acute and late genitourinary (GU) toxicities occurred in 1.4% (95% CI: 0.8-2.3) and 3.7% (95% CI: 2.6-4.9) of patients, respectively. Severe acute and late gastrointestinal (GI) toxicities were reported in 0.5% (95% CI: 0.2-1.1) and 0.4% (95% CI: 0.1-1.0) of patients, respectively. Combined severe GU and GI toxicities were observed in 5.8% (95% CI: 4.5-7.4) and 1.3% (95% CI: 0.7-2.2) of patients, respectively. CONCLUSIONS: This study provides a comprehensive assessment of toxicities and conducts a pooled analysis of RFS for salvage SBRT in radio-recurrent PCa. Factors such as whole-gland irradiation, and higher BED show promise as prognostic indicators for RFS. However, confirmation through randomized controlled trials is essential due to the low levels of evidence and study heterogeneity.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Meng Y, Liu J, Shen B, et al. Evaluation of the safety and efficacy of stereotactic body radiotherapy for radio-recurrent prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 39702471. doi:10.1038/s41391-024-00927-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。